Cara Therapeutics (CARA) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

CARA Cara Therapeutics

Watchlist

0.243
-0.012-4.71%

Close Jun 18 16:00 ET

0.242
-0.001-0.25%

Post 19:55 ET

13.26MMarket Cap-107P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Marijuana Stock Movers For June 19, 2024
GAINERS:Elixinol Wellness (OTC:ELLXF) shares closed up 82.00% at $0.00Target Group (OTC:CBDY) shares closed up 15.38% at $0.00Psychemedics (NASDAQ:PMD) shares closed up 10.88% at $2.35Cannabix Technol
Benzinga16:30 ET
Benign Growth For Cara Therapeutics, Inc. (NASDAQ:CARA) Underpins Stock's 68% Plummet
Cara Therapeutics, Inc. (NASDAQ:CARA) shareholders that were waiting for something to happen have been dealt a blow with a 68% share price drop in the last month. The recent drop completes a disast
Simply Wall StJun 19 07:50 ET
Cara Therapeutics to Idle 70% Workforce, Explore Alternatives After Scrapping Notalgia Paresthetica Program
Cara Therapeutics (CARA) late Tuesday disclosed plans to explore strategic alternatives and lay off 70% workforce after discontinuing work on its difelikefalin drug candidate last week for failing to
MT NewswiresJun 18 17:11 ET
Express News | Cara Therapeutics - Approved Reduction in Company's Workforce by Approximately 70%, Which Company Expects to Substantially Complete by June 30, 2024
ReutersJun 18 16:19 ET
Express News | Cara Therapeutics Inc -Costs Are Expected to Be Substantially Recognized in the Second and Third Quarter of 2024
ReutersJun 18 16:19 ET
Express News | Cara Therapeutics Inc - Anticipates Recognizing About $2.6 Mln in Total Charges in Connection With Reduction in Force
ReutersJun 18 16:18 ET

Comments

Jaguar8

Jun 13 04:02

NEWS

$Cara Therapeutics(CARA.US)$
Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica
Cara Therapeutics announced disappointing results from Part A of their KOURAGE-1 study, evaluating oral difelikefalin for notalgia paresthetica (NP). The drug did not show meaningful clinical benefit over placebo at any dose, leading the company to discontinue the clinical program in NP. The Phase 2/3 trial involved 214 patients, and despite the...

Sean Parker

May 1 18:51

Hope it goes well

$Cara Therapeutics(CARA.US)$
CERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes30/04/2024 09:00AM ET
SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo") an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic a...

Moomoo AI

Dec 31, 2023 22:15

Cara Therapeutics' low P/S ratio reflects its declining revenues and bleak future growth projection. Per investors, the company's future may not yield a significant revenue improvement.